NAD precursors as antiteratogens against aminothiadiazole Supported by NIH Grant HD00400.
dc.contributor.author | Beaudoin, Allan R. | en_US |
dc.date.accessioned | 2006-04-28T16:41:46Z | |
dc.date.available | 2006-04-28T16:41:46Z | |
dc.date.issued | 1976-02 | en_US |
dc.identifier.citation | Beaudoin, Allan R. (1976)."NAD precursors as antiteratogens against aminothiadiazole Supported by NIH Grant HD00400. ." Teratology 13(1): 95-99. <http://hdl.handle.net/2027.42/38129> | en_US |
dc.identifier.issn | 0040-3709 | en_US |
dc.identifier.issn | 1096-9926 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/38129 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=176745&dopt=citation | en_US |
dc.description.abstract | The teratogen 2-amino-l,3,4-thiadiazole (ATDA) is an antagonist of nicotinamide, and may act by interfering with the synthesis or utilization of the coenzyme nicotinamide adenine dinucleotide (NAD). Several compounds that can be converted to NAD were tested as antiteratogens against ATDA. At day 11 of gestation (sperm day = day 0) pregnant Wistar-derived rats were given single ip injections of ATDA (100 mg/kg), or ATDA immediately followed by the suspected antiteratogen ip or by gavage, or the antiteratogen alone. Compounds tested were NAD, nicotinamide, nicotinic acid, quinolinic acid, kynurenine sulfate, and L-tryptophan, in doses of 10–200 mg per animal. At autopsy (day 20) fetuses were recovered and examined. It was found that each antiteratogen significantly reduced the frequency of ATDA-induced resorptions and malformations. At certain doses each antiteratogen gave complete protection against ATDA-induced malformations in some, but not all, litters. These results support the hypothesis that ADTA interferes with the synthesis or utilization of NAD and suggest that substances converted to NAD act as antiteratogens against ATDA. | en_US |
dc.format.extent | 281560 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cell & Developmental Biology | en_US |
dc.title | NAD precursors as antiteratogens against aminothiadiazole Supported by NIH Grant HD00400. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Anatomy, The University of Michigan, Ann Arbor, Michigan 48104 | en_US |
dc.identifier.pmid | 176745 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/38129/1/1420130114_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/tera.1420130114 | en_US |
dc.identifier.source | Teratology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.